Recent FDA advisory committee meetings have resulted in negative outcomes for multiple drug candidates. Otsuka Pharmaceutical's combination therapy for PTSD, Rexulti with Zoloft, failed to secure committee support due to mixed trial results and insufficient data. Similarly, GSK's attempt to restore Blenrep (an antibody-drug conjugate) in multiple myeloma was rebuffed due to safety concerns, including severe ocular toxicity and patient demographics. Bristol Myers Squibb’s anemia drug Reblozyl did not meet its primary endpoint in a phase III myelofibrosis study but showed some secondary benefits, prompting continued regulatory discussions. These outcomes reflect ongoing scrutiny of safety and efficacy in challenging therapeutic areas.